Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 11,000 da Vinci systems in hospitals worldwide, with more than 6,600 installations in the US and a growing number in emerging markets.
Last trade$432.52
Day change-$5.235 (-1.20%)
Day range$428.78 – $441.28
Volume1,514,061
Market cap$151.74B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$151.74B
Price / earnings
51.31×
Price / book
9.49×
Price / sales
13.11×
EV / sales
12.85×
EV / EBITDA
33.36×
Profitability
Earnings per share
$8.53
Return on assets
15.28%
Return on equity
18.5%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.33×
Quick ratio
2.49×
Cash ratio
1.18×
Cash flow
Price / cash flow
37.11×
Price / free cash flow
42.17×
Free cash flow
$3.6B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ISRG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.05B
$2.89B
$2.77B
$2.87B
$2.51B
$2.44B
$2.25B
$2.41B
Cost of revenue
$964.4M
$931.9M
$940.3M
$961.9M
$842.7M
$822.1M
$795.7M
$771.3M
Gross profit
$2.08B
$1.96B
$1.83B
$1.9B
$1.66B
$1.62B
$1.46B
$1.64B
Selling, general and administrative
$633.4M
$617.9M
$613.3M
$687.1M
$573.3M
$561.2M
$563.4M
$612.6M
Research and development
$408.3M
$370.6M
$361.9M
$352.9M
$329.4M
$313.3M
$316.2M
$294.7M
Total operating expenses
$1.49B
$988.5M
$975.2M
$1.04B
$902.7M
$874.5M
$879.6M
$907.3M
Operating income
$592.6M
$971.9M
$855.3M
$864.3M
$759.7M
$743.4M
$578.1M
$734.9M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$668.4M
$1.05B
$940.4M
$955.6M
$855.2M
$832.1M
$668.5M
$809.8M
Income taxes
$144M
$231.4M
$114.4M
$156.1M
$146M
$167.9M
-$35.2M
$121.8M
Net income
$524.4M
$823.2M
$826M
$799.5M
$709.2M
$664.2M
$703.7M
$688M
Net income attributable to common shareholders
$522.8M
$818.1M
$821.5M
$794.8M
$704.4M
$658.4M
$698.4M
$685.7M
EBITDA
$1.07B
$1.01B
$876.4M
$1.5B
$772.6M
$755.7M
$590.2M
$1.19B
Basic earnings per share
$1.50
$2.31
$2.31
$2.24
$1.98
$1.84
$1.95
$1.92
Diluted earnings per share
$1.49
$2.29
$2.28
$2.21
$1.95
$1.81
$1.92
$1.88
Recent news
Company coverage with links to the original publishers.
Intuitive Surgical (ISRG) has been heavily searched by investors and shows strong fundamentals with a Zacks Rank #2 (Buy) rating. The company is expected to post 17% year-over-year earnings growth for the current quarter and 25.9% for the fiscal year, with consensus estimates revised upward by 5.6% over the past month. However, the stock is trading at a premium valuation (F grade) compared to peers, and revenue growth forecasts show 18.4% and 11.6% increases for current and next fiscal years respectively.
GE HealthCare Technologies (GEHC) is well-positioned for growth with a record $23.7 billion backlog (up 12%), strong Pharmaceutical Diagnostics revenue growth, and raised 2026 guidance. However, persistent component inflation, tariff uncertainty, and China's fragile recovery pose risks to margin expansion.
Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.
Doximity announced an expansion of its AI-powered clinical tools partnership with NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine. The collaboration includes Doximity Ask (clinical decision support integrated with Epic EHR) and Doximity Scribe (patient documentation and dictation). The company also launched DoseCheck, a safety feature reducing dosing errors by over 99%. Despite the positive developments, DOCS stock has declined 24.7% year-to-date.
Koninklijke Philips reported strong equipment order intake growth of 8% with Diagnosis & Treatment orders surging nearly 20%, and Personal Health sales rising 8%. However, ultrasound manufacturing delays, China's pricing pressure from centralized procurement, and inflation concerns pose significant risks to profitability and growth trajectory. The company maintains a Zacks Rank #3 (Hold) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.